Eli Lilly’s Omvoh (mirikizumab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat moderately to severely active Crohn’s disease in adults on the NHS in ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly and Company LLY has reached a significant support level, ... Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.

Shares of companies that pay reliable dividends can typically be bought and held forever. These five have paid dividends for ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will ...

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, respectively, with AstraZeneca coming in a respectable third with 14 per cent.

California legislators have pulled Medicaid coverage for pricey weight loss drugs like Zepbound to patch a $12 billion budget ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...